ストックスクリーナーアプリを入手
30.03
0.30%
0.09
プレマーケット:
30.13
0.10
+0.33%
Travere Therapeutics Inc (TVTX) 最新ニュース
TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm - PR Newswire
Travere therapeutics CEO Dube sells $1.8 million in TVTX stock By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) Stock Analysis: Exploring a 40% Upside in Rare Disease Biotechnology - DirectorsTalk Interviews
TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses - GlobeNewswire
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? - AOL.com
Universal Beteiligungs und Servicegesellschaft mbH Boosts Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
BofA remains positive on Travere despite FDA decision delay for Filspari - MSN
Trading the Move, Not the Narrative: (TVTX) Edition - Stock Traders Daily
Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics - Intellectia AI
Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook - MSN
Benign Growth For Travere Therapeutics, Inc. (NASDAQ:TVTX) Underpins Stock's 27% Plummet - simplywall.st
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX) and Boston Scientific (BSX) - The Globe and Mail
Emerald Mutual Fund Advisers Trust Buys 59,514 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
How liquid is Travere Therapeutics Inc. stockPortfolio Performance Report & Consistent Profit Trade Alerts - mfd.ru
BofA Remains Positive on Travere Despite FDA Decision Delay for Filspari - Insider Monkey
Emerald Advisers LLC Increases Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
14 Best Mid-Cap Growth Stocks to Buy Right Now - Insider Monkey
Travere, Ligand hammered on a surprise delay for their linchpin drug - MSN
Curious about Travere (TVTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics - MSN
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells $273,400.00 in Stock - MarketBeat
Is Travere Therapeutics Inc Gaining or Losing Market Support? - Benzinga
Top 3 Health Care Stocks That Could Blast Off This Month - Benzinga
Merger Talk: Whats the analyst consensus on SDOWEarnings Overview Report & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Travere shares sink as FDA seeks further clarification on kidney drug - MSN
Travere Therapeutics Stock Climbs After FDA Eases FILSPARI Monitoring Requirements - MSN
Travere therapeutics CFO sells $104,463 in stock - MSN
Stephens Investment Management Group LLC Purchases Shares of 1,599,668 Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics : Investor Fact Sheet - marketscreener.com
Rate Hike: Is Travere Therapeutics Inc stock heavily shortedMarket Trend Review & Low Risk Entry Point Guides - baoquankhu1.vn
Chipmakers Recap: Whats the MACD signal for Travere Therapeutics IncMarket Activity Report & Technical Confirmation Alerts - baoquankhu1.vn
Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses - TradingView
Two Biotechs to Play in Uncertain Times - TheStreet Pro
First Week of September 18th Options Trading For Travere Therapeutics (TVTX) - Nasdaq
TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm - Chartmill
Travere plummets as FDA extends Filspari review for rare kidney disorder - MSN
Equities Analysts Issue Forecasts for TVTX FY2030 Earnings - MarketBeat
Travere Therapeutics 2026 Outlook: Filspari Momentum, FSGS FDA Delay, And Market Potential - Seeking Alpha
Why Did TVTX Stock Crash 30% In Pre-Market Today? - Stocktwits
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA - Finviz
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Travere Therapeutics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through the Firm's Investigation - ACCESS Newswire
Is Travere Therapeutics (TVTX) Pricing Reflect Long Term Value After Recent Share Price Pullback - Yahoo Finance
Travere Therapeutics (TVTX) Is Down 18.7% After FDA Extends FILSPARI FSGS Review Timeline – Has The Bull Case Changed? - Yahoo Finance
INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLC - GlobeNewswire
(TVTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Travere stock rises as FDA extends Filspari review timeline - Investing.com
Travere stock rises as FDA extends Filspari review timeline By Investing.com - Investing.com UK
Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
US FDA extends review of Travere’s drug for rare kidney disease - whtc.com
Biggest stock movers Wednesday: INTC, WRD, TVTX, and more (RIVN:NASDAQ) - Seeking Alpha
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS - BioSpace
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):